Lindahl advises Corline Biomedical AB on directed share issue
Lindahl is acting as legal adviser to Corline Biomedical AB (publ) in connection with a directed share issue amounting to approximately SEK 23 million.
Through the share issue, Corline Biomedical will receive approximately SEK 23 million before deduction of issue costs. In addition, the company strengthens its shareholder base with a long-term and international investor, Eiffel Investment Group, to which the issue is directed.
Corline Biomedical develops and sells medical technology solutions. The company's shares are listed on Nasdaq First North Growth Market.
Lindahl's team consists of Mattias Prage and Olle Swärd Brattström.
Do you want to know more? Contact:
Mattias Prage
Partner | AdvokatOlle Swärd Brattström
AssociateCarousel items
-
Cases and transactions
7/13/2026
Lindahl Advises Bokusgruppen AB (publ) on the Acquisition of Pen Store Sthlm AB
Lindahl has advised Bokusgruppen on its acquisition of Pen Store, the leading Nordic retailer of pens and artists' materials serving customers across the EU.
-
News articles
7/7/2026
Lindahl included among Sweden's ten most reputable patent firms for the second consecutive year
For the second consecutive year, Lindahl has been named among Sweden's ten most reputable patent law firms by The Patent Lawyer Magazine – a testament to the firm's strong expertise and long-term commitment in intellectual property law.
-
Portraits
7/3/2026
Jesper on business-oriented legal advice in energy: "It is not enough for the advice to be correct"
Lindahl's energy team is recognised in Legal 500 for combining deep regulatory expertise with broad commercial legal experience – find out how they support clients in a rapidly evolving sector.
-
Knowledge
6/29/2026
The scope of the Swedish FDI Act is expanded – is your business affected?
MCF's new regulation (MCFFS 2026:13) expands the scope of the Swedish FDI Act from 15 July 2026. Is your business affected? Read about the key changes.
-
Read more news and insights?
